Intranasal Insulin for Prevention of Type 1 Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.

Verified August 2005 by University of Turku.
Recruitment status was Recruiting

Sponsor:

Collaborators:

Oulu University Hospital

University of Tampere

Helsinki University

Information provided by:

University of Turku

ClinicalTrials.gov Identifier:

NCT00223613

First received: September 13, 2005

Last updated: September 18, 2006

Last verified: August 2005

History of Changes

Purpose

Children born in Turku, Oulu and Tampere university cities in Finland are screened at birth for HLA alleles that carry increased risk to or protection from development of type 1 diabetes. Children carrying increased risk are followed at 3-12-month intervals for development of diabetes-associated autoantibodies. Children having at least two types of autoantibodies (of the four measured) in at least two consecutively drawn samples are randomized to receive daily intranasal insulin or placebo in a double-blinded 1:1 trial. Hypothesis is that intranasal insulin delays or prevents development of clinical type 1 diabetes. The primary outcome measure is development of clinical diabetes.

Condition	Intervention	Phase
Type 1 Diabetes	Drug: daily intranasal administration of insulin	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention
Official Title:	Intranasal Insulin for Prevention of Type 1 Diabetes in Children Carrying Increased HLA-Conferred Genetic Risk

Resource links provided by NLM:

Genetics Home Reference related topics: type 1 diabetes

MedlinePlus related topics: Diabetes Medicines Diabetes Type 1

Drug Information available for: Insulin Insulin human

U.S. FDA Resources

Further study details as provided by University of Turku:

Primary Outcome Measures:

Development of clinical type 1 diabetes

Secondary Outcome Measures:

Number and concentration in serum of diabetes-associated autoantibodies (ICA, IAA, GADA and IA-2A)
Responses to intravenous glucose tolerance test
Possible side effects of therapy including hypoglycemia
Changes in serum metabolite patterns (metabolomics)


Estimated Enrollment:	240
Study Start Date:	August 1997
Estimated Study Completion Date:	August 2005

Detailed Description:

Children born in Turku, Oulu and Tampere university cities in Finland are screened at birth for the HLA-DQB1 and DQA1 alleles that carry increased risk to or protection from development of type 1 diabetes. Children carrying increased risk are followed at 3-month intervals until 2 years of age and then at 6-12-month intervals until,15 years of age for development of diabetes-associated autoantibodies (autoantibodies against islet cells, insulin, glutamic acid decarboxylase and IA-2 protein). Children having at least two types of autoantibodies of the four measured in at least two consecutively drawn samples are randomized to receive daily intranasal insulin or placebo in a double-blinded 1:1 trial. Hypothesis is that intranasal insulin delays or prevents development of clinical type 1 diabetes. The primary outcome measure is development of clinical diabetes, but serum concentrations of autoantibodies, responses to intravenous glucose tolerance test and possible side effects of therapy are also closely monitored.

Eligibility


Ages Eligible for Study:	1 Year to 15 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

children carrying HLA-conferred genetic risk for developing type 1 diabetes
have had at least two types of autoantibodies of ICA, IAA, GADA and IA-2A in at least two consecutive blood samples drawn at least 3 months apart
age at least one year

Exclusion Criteria:

severe other disease
age above 15 years

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00223613

Contacts


Contact: Olli G Simell, MD, PhD	+358-2-313-2466	olli.simell@utu.fi
Contact: Tuula T Simell, MPH, PhD	+358-2-313-3427	tuula.simell@utu.fi

Locations


Finland
Department of Pediatrics, University of Turku	Recruiting
Turku, Finland, FI-20520
Contact: Tuula T Simell, MPH, PhD +358-2-313-3427 tuula.simell@utu.fi
Contact: Birgitta Nurmi, RN +358-2-313-2465 birgitta.nurmi@tyks.fi
Sub-Investigator: Kirsti Näntö-Salonen, MD, PhD

Sponsors and Collaborators

University of Turku

Oulu University Hospital

University of Tampere

Helsinki University

Investigators


Principal Investigator:	Olli G Simell, MD, PhD	University of Turku, Turku, Finland

More Information

Additional Information:

Description of the entire DIPP study This link exits the ClinicalTrials.gov site

Publications:

Kupila A, Sipilä J, Keskinen P, Simell T, Knip M, Pulkki K, Simell O. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults. Diabetes Metab Res Rev. 2003 Sep-Oct;19(5):415-20.

Keskinen P, Korhonen S, Kupila A, Veijola R, Erkkilä S, Savolainen H, Arvilommi P, Simell T, Ilonen J, Knip M, Simell O. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia. 2002 Dec;45(12):1639-48. Epub 2002 Oct 30.

Kupila A, Keskinen P, Simell T, Erkkilä S, Arvilommi P, Korhonen S, Kimpimäki T, Sjöroos M, Ronkainen M, Ilonen J, Knip M, Simell O. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes. 2002 Mar;51(3):646-51.

Hermann R, Mantere J, Lipponen K, Veijola R, Soltesz G, Otonkoski T, Simell O, Knip M, Ilonen J. Lack of association of PAX4 gene with type 1 diabetes in the Finnish and Hungarian populations. Diabetes. 2005 Sep;54(9):2816-9.

Kukko M, Toivonen A, Kupila A, Korhonen S, Keskinen P, Veijola R, Virtanen SM, Ilonen J, Simell O, Knip M. Familial clustering of beta-cell autoimmunity in initially non-diabetic children. Diabetes Metab Res Rev. 2006 Jan-Feb;22(1):53-8.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Virtanen SM, Nevalainen J, Kronberg-Kippilä C, Ahonen S, Tapanainen H, Uusitalo L, Takkinen HM, Niinistö S, Ovaskainen ML, Kenward MG, Veijola R, Ilonen J, Simell O, Knip M. Food consumption and advanced β cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes: a nested case-control design. Am J Clin Nutr. 2012 Feb;95(2):471-8. doi: 10.3945/ajcn.111.018879. Epub 2012 Jan 11.

Goldstein E, Hermann R, Renfors TJ, Näntö-Salonen KM, Korhonen T, Kärkkäinen M, Veijola RK, Knip M, Simell TT, Simell OG. From genetic risk awareness to overt type 1 diabetes: parental stress in a placebo-controlled prevention trial. Diabetes Care. 2009 Dec;32(12):2181-3. doi: 10.2337/dc09-0423. Epub 2009 Sep 14.

Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008 Nov 15;372(9651):1746-55. doi: 10.1016/S0140-6736(08)61309-4. Epub 2008 Sep 22.


ClinicalTrials.gov Identifier:	NCT00223613 History of Changes
Other Study ID Numbers:	DIPP19942014, JDRF File # 4-1999-731
Study First Received:	September 13, 2005
Last Updated:	September 18, 2006
Health Authority:	Finland: Ethics Committee

Keywords provided by University of Turku:


diabetes juvenile diabetes insulin deficiency

Additional relevant MeSH terms:


Diabetes Mellitus, Type 1 Autoimmune Diseases Diabetes Mellitus Endocrine System Diseases	Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases

ClinicalTrials.gov processed this record on March 03, 2015

To Top